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Abstract 
8-Hydroxydeoxyguanosine (80HDG) is a specific marker of oxidative damage to DNA. We have observed that patients with SLE (systemic lupus 
erythematosus), have undetectable l vels of urinary 8OHDG by HPLC. Further analysis by GC-MS confirmed that levels of 80HDG in SLE urine 
were lo’-fold lower than in an age- and sex-matched control group. Experiments utilising cultures of SLE and normal lymphocytes exposed to H,O, 
confirmed the impaired ability of SLE lymphocytes to repair 80HDG. We subsequently observed in SLE patients that 8OHDG had accumulated in 
low molecular weight DNA associated with circulating immune complexes. We suggest hat oxygen radicals may induce pathology in SLE by 
maintaining the presence of an antigenic form of DNA in the circulation. 
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Chronic infla~ation is associated with considerable 
tissue injury. It has been postulated that this may result 
from perpetual stimulation of phagocytic cells by bacte- 
rial and i~unolo~cal stimuli activating the membrane- 
bound NADPH oxidase and releasing reactive oxygen 
species (ROS) [I]. ROS are formed from oxygen in one- 
electron reduction reactions and include superoxide 
anion, hydrogen peroxide and hydroxyl radical. Of 
these, the hydroxyl radical has a very short half-life, 
reacting at diffusion controlled rates with many cellular 
biomolecules. 
In some disease states, the inflammatory process and 
thus the production of ROS may be amplified in the 
confined space of a certain tissue. In rheumatoid arthritis 
(RA), inflammation is usually confined to the joint and 
is thought to contribute to the joint deformities com- 
monly associated with the disease [Z]. Although several 
research groups believe that the production of ROS in 
infla~atory joint disease is relevant o the disease proc- 
ess [3,4], there has been no direct demonstration that the 
highly reactive hydroxyl radical is formed in vivo in an 
inflamed joint. The reasons for this are twofold. Firstly, 
the hydroxyl radical is very reactive, diffusing only 1.5 
nm before reacting with a target molecule [5]. Secondly, 
previous attempts to measure interactions between hy- 
droxyl radicals and biomolecules, predominantly lipids, 
have relied on semi-quantitative assays such as (i) the 
thiobarbituric acid (TBA) assay, which measures lipid 
peroxidation, but is non-speci~c and subject to interfer- 
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ence from prostaglandins (a major problem in inflamma- 
tion research [6]; and (ii) the diene conjugation assay, 
another non-specific measure of lipid peroxidation 173. In 
spite of this, ROS have been shown to readily damage 
not only lipids but also proteins [2,7,8], and DNA in- 
tracellularly [9,10]. Damage to DNA induces strand 
breaks [l 11, sister chromatid exchanges and the subse- 
quent production of clastogenic factors [12], and altera- 
tions in base structure [13]. Monitoring DNA damage 
induced specifically by ROS has been the strategy used 
in this present study to provide evidence of oxidative 
damage to DNA in vivo. 
Formation of the altered base, SOHDG, has been 
shown to be a very sensitive marker of ROE&induced 
damage [14,151. Its production has been affirmed in vitro 
following exposure of DNA to y-radiation [ 161, UV light 
[ 171, hydrogen peroxide [ 181 and PMA-stimulated neu- 
trophik [19]. It is believed to be formed by the addition 
of a hydroxyl radical to C-8 of deoxyguanosine, and can 
be measured using high performance liquid chromatog- 
raphy (HPLC) with electrochemical detection following 
enzymic digestion of DNA [20]. 
This paper describes the use of HPLC and gas chrom- 
atography mass spectroscopy with selected ion monitor- 
ing (GC-MS/SIM) assays to measure 80HDG as a sensi- 
tive and specific marker of ROS-induced damage to 
DNA, and discusses the relationship between this oxida- 
tive change and infla~atory autoi~une pathology. 
2. Materials aud methods 
2.1. Patient groups 
Early morning urine samples and plasma samples (venous blood 
collected into heparin and centrifuged for 30 min at 300 x g) were 
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collected from 33 SLE patients with normal renal function (all satisfied 
the nreliminarv criteria of the ARA for diaanosis of SLE) (29 female, 
4 male, age range 2w4, median = 39), l?l RA patients‘diagnosed 
according to standard ARA criteria (9 female, 1 male, age range 57-80, 
median = 67) and two groups of 10 normal controls: young normal 
controls (8 female, 2 male, age range 2&47, median = 26) not differing 
in age or sex from the SLE group, and elderly normal controls (9 
female, 2 male, age range 62-82, median = 70) not differing in age or 
sex from the RA patients. RA patients were prospectively selected to 
have an active infiammatory status based on-an elevated level of the 
acute phase protein, C-reactive protein (CRP). In this group CRP 
values ranged from 42-123 mgll, median = 64 mg/l (normal range < 6 
mg/l). The 33 SLE patients tudied had a range ofinflammatory disease 
activity as determined by levels of erythrocyte sedimentation rate (ESR) 
(5-92 mm/h, median = 26 mm/h, normal range < 20 mm/h). 
Two different indicators of inflammatory status were used because 
CRP is not a good indicator of inflammatory activity in SLE, since 
disease-associated anaemia can effect ESR but not CRP values in RA. 
All samples were stored at -20°C prior to analysis. 
2.2. Preparation of urine samples 
Early morning urine sample (0.5 ml) was added to a 1 ml C-18 
SEP-PAK column (Waters, Watford, UK) preconditioned with 10 ml 
methanol and 10 ml water. The eluant was discarded and the column 
washed with 5 x 1 ml of 5% aqueous methanol. The fraction containing 
8OHDG as the nucleoside in the highest concentration was then eluted 
with 3 x 1 ml of 15% aqueous methanol. The eluant was evaporated to 
dryness and the sample resuspended in 200 ~1 HPLC mobile phase 
buffer. Recoveries using spiked urine sampIes were consistently 65 
70%. This separation procedure using reverse-phase material selectively 
removed many electrochemically active compounds present in high 
concentration in urine that would otherwise have masked the presence 
of picomolar quantities of the nucleoside, 8OHDG. All urine measure- 
ments of 80HDG were expressed relative to creatinine to correct for 
differences in urine dilution [20]. 
2.3. Isolation of DNA from cryoprecipitates 
Plasma samples were incubated at 4°C for 7 days to induce cryopre- 
cipitation. The pellet formed was washed in PBS and the DNA ex- 
tracted using proteinase K (100 &ml; Sigma, Poole, Dorset) and 1% 
SDS (Sigma) in a 1 ml volume of 20 mM EDTA, pH 8.0, added to the 
1 ml volume (PBS) of resolubilised immune complex. The mixture was 
incubated at 65°C for 30 min and protein removed by extracting three 
times with ‘/z volume of phenol and i/Z vol. of chloroform (British Drug 
Houses, Poole, Dorset). To precipitate the DNA, 2 ~01s. of cold ethanol 
in the presence of 0.3 M sodium acetate were added to the aqueous 
phase which was then left at -20°C for 24 h. The DNA was washed 
with 70% ethanol, lyophilised and resuspended in 100 pl Tris EDTA, 
pH 8.0. Prior to analysis by HPLC, the DNA was digested as described 
by Beland [21]. 
2.4. Analysis of immune complexed DNA 
Agarose gel electrophoresis was used to determine the purity of DNA 
isolated from immune complexes and also to estimate its size. Using a 
mini gel annaratus 0.2 g of agarose was dissolved in 20 ml 89 mM 
Tris-borate buffer (TBES, pH 8.0, to give a gel concentration of 1%. 
Ethidium bromide was added to a final con~ntration of 0.75 &/ml. 20 
pl of DNA mixed with 5 ~1 loading buffer (0.25% Bromphenol blue, 
0.25% xylene cyan01 and 40% w/v sucrose in water) and loaded onto 
the gel and the electrophoresis was carried out at 70 V for 30 min in 
TBE. 
2.5. Lymphocyte preparat~~ subjected to oxiaktive stress 
Peripheral blood monocytes (PBMC) were isolated from the periph- 
eral blood of patients with SLE and normal controls and re-suspended 
to 1 x 106/ml and cultured in 24-well plates ina volume of 2 ml complete 
culture medium. 
These PBMC derived from normal and SLE cells were incubated 
with or without 200pM HsO, for 7 days. At intervals during this period 
cell viability was determined and cells and su~ma~nts were collected. 
Supematants were replaced by fresh culture medium after sampling at 
each time point between 0 and 7 days. The cells were separated by 
centrifugation at 300 x g for 10 min at 4’C, washed twice in PBS and 
re-suspended to log/ml in ice-cold TBE. DNA was isolated from the 
cells according to the method of Maniatis et al. 1221 and digested as for 
immune complexed DNA before analysis by HPLCIECD. 2 ~01s. of 
ice-cold ethanol were added to each sample of supematant collected 
after centrifugation. Any DNA was allowed to precipitate at -20°C for 
24 h and pelleted by centrifugation at 0°C for 10 min in an Eppendorf 
centrifuge. The remaining supernatant was freeze-dried and resus- 
pended in 1 ml of sterile water. Ethanol precipitation of the superna- 
tants was used to remove large fragments of DNA arising from cell 
death so that the only detectable 8OHDG was from individual bases or 
small fragments of DNA arising from excision repair. 10 ~1 of superna- 
tant digested and treated as DNA was analysed by HPLC. 
2.6. Hydrolysis and derivitisation of DNA samples 
Prior to analysis by GC-MS/SIM, DNA samples were hydrolysed 
with 1 ml of formic acid (88%; Mallinckrodt Inc., Paris, KY) in evacu- 
ated and sealed tubes at 150°C for 30 min. This removes the ribose 
residue and, as a result, in contrast o the HPLC method, the derivatives 
of deoxyguanosine (guanine) and deoxyadenosine (adenine) are meas- 
ured. After hydrolysis, samples were lyophilised and trimethylsilylated 
with 0.25 ml of a 1.51 mixture of bis (trimethylsily)-trifluoroacetamide 
(BSTFA, containing I% tr~ethylchlorosilane; Sigma) and acetonitrile, 
in pol~etrafluor~~ylene capped hypovials (both from Pierce Chemi- 
cal Co., Rockford, IL) by heating at 13O’C for 30 min. Urine samples 
were derivatised only as for DNA. 
2.7. Characterisation of DNA base damage 
Analysis of the prepared urine and DNA samples was either by: 
(i) HPLC using isocratic reverse-phase chromatography - DNA bases 
were analysed on an ODS 5 pm 25 cm column with a guard column of 
pellicnlar ODS material (both from Technical, Stockport, Cheshire, 
UK), at a flow rate 0.8 ml/min using a mobile phase of 30 mM sodium 
hydroxide, 10 mM acetic acid, 41 mM sodium acetate and 12.5 mM 
citric acid, pH 5, containing 10% methanol. UV detection was at 254 
run and 80HDG was detected by ECD using a glassy carbon working 
electrode at an applied potential of +0.6 V vs. Ag/AgCl; or, (ii) gas 
chromatography mass s~tro~opy with selected-ion monito~ng (GC- 
MS&M) - hydrolysed and derivatised DNA samples and derivatised 
urine samples were analysed using a mass selective detector controlled 
by a computer work station and interfaced to a gas chromatograph (all 
instruments from Hewlett-Packard Co., Avondale, PA, with model 
numbers S970B, S97OC, and S890A, respectively). The injection port 
and the ion source were kent at 250°C. The GC-MS interface was 
mainlined at 270°C. Se~~tions were carried out on a fused silica 
capillary column (12.5 m x 0.32 mm id.) coated with crosslinked 5% 
phenylmethyl silicone gum phase (film thickness, 0.17pM). The column 
was programmed from 120°C to 250°C at 8”C/min, after 2 min at 
12O’C. Helium was used as the carrier gas at an inlet pressure of 10 kPa. 
Samples were injected using the splitless mode. Mass spectra were 
obtained at 70 eV. Authentic samples of isobarbituric acid (5- 
hydroxyura~~ Sigma), 4,6-diamino-5-fo~~idopyrimidine (Sig- 
ma). and 2-a~no-6.8”d~vdroxvuurine (8hydroxyguanine; Chemical 
Dynamics Corp., South -Plainfield, Nj), were -available commer- 
cially. 
2.8. Quantitation of DNA base damage 
DNA base products were quantitatively measured using 8-azaaden- 
ine (Sigma) as an internal standard. Aliquots of the internal standard 
were added to the DNA samples. The samples were then lyophilised, 
hvdrolvsed. trimethvlsilvlated and analvsed bv GC-MSISIM. Ion cur- 
rents of the typical‘ions of the DNA base products were monitored 
along with the m/z 265 ion of the trimethylsilyl derivative of 8-azaaden- 
ine. 
3. Results 
3.1. Urinary excretion of 80HDG 
To investigate the presence of ROS-induced damage 
in DNA from RA and SLE patients, urinary excretion 
of SOHDG was measured both by HPLC and GC-MS. 
Early morning urine samples were collected and applied 
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Fig. 1. Log plot of levels of 8OHDG found in early morning urine samples of SLE patients (n = 33), young normal controls (n = lo), RA patients 
(n = 10) and elderly controls (n = 10) detected by HPLUECD. The figure shows the median and ranges for each of the groups. All the results for 
the SLE group are below the detection limit of the assay. Each point plotted represents he mean of triplicate urine samples analysed for each person 
studied. The retention time of 80HDG was consistently 17.2 f. 0.3 min. 
to a Cl8 mini column to selectively remove compounds 
that interfered with the electrochemical detection and 
GC-MS procedures. Measurement of 80HDG was made 
relative to creatinine to correct for urine concentration. 
Of the samples from 33 SLE patients with normal renal 
function which were analysed, levels of 80HDG excreted 
were undetectable by HPLC in all samples, i.e. levels 
were < 0.1 pmol/~mol creatinine. The normal range es- 
tablished from the two groups of controls by HPLC was 
1 .(X5.2 pmol80HDG/pmol creatinine for the young con- 
trols and 0.75-3.9 pmol80HDG/pmol creatinine for the 
elderly controls. Results from the patient group with 
active RA showed that the level of urinary excretion of 
80HDG was signifkantly elevated when compared to 
normal (25-32 pmol@mol creatinine; P < 0.001; Fig. 1). 
In order to confkn the HPLC results indicating unde- 
tectable levels of 80HDG in SLE urine samples, a ran- 
dom selection of specimens were also analysed by GC- 
MWSIM, a well-established technique for identification 
of compounds on the basis of their individual molecular 
weights and molecular weight fragments produced dur- 
ing atomic bombardment. It was found that levels of 
80HDG in urine samples from SLE patients were detect- 
able in the femtomolar range by GC-MS/SIM (Fig. 2A), 
previously determined to be below the limits of detection 
of the HPLC assay. 
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Fig. 2. (A) Identification of modified bases in SLE urine. Ion current profiles of the ions at m/z 440/455 and 352. Peak identification: 1, 8- 
hydroxyguanine (3 fmol80HDG/pg DNA); 2, 8-hydroxyadenine (7 pmol80HDGlpg DNA). (B) Mass spectra of modified DNA bases derived from 
circulating plasma complexes in a typical SLE patient. Partial mass spectra obtained from the monitored ions and their abundance at the elution 
positions; 1, identified as I-hydroxyadenine and 2, identified as I-hydroxyguanine. 
3.2. Detection of 80HDG in immune complexes 
In order to try and establish the fate of 80HDG in 
SLE, and based on a working hypothesis that abnor- 
mally low levels of 80HDG in SLE urine suggested a lack 
of repair of this adduct, DNA present in cryoprecipitates 
from SLE plasma was examined for the presence of 
80HDG. 
In contrast to the results obtained for the SLE urine 
samples, levels of 80HDG found in the DNA isolated 
from immune complexes were very high (0.38-3.6 pmol 
SOHDGlpg DNA) and were detectable both by HPLC 
and GC-MS (Table 1). These levels are of the order of 
lOO-times greater than the range determined by Richter 
et al. for nuclear DNA (0.025 pmol/pg DNA) [23], con- 
sidered to be a reflection of normal oxidative stress to the 
cell. DNA was isolated from cryoprecipitates of RA pa- 
tients as a control group, as for the SLE patients; low 
levels of DNA were found in the complexes from rheu- 
matoids (2-8 pg DNA compared with 100-270 pg DNA 
in the SLE group for the same volume of plasma, 
P < 0.001; and levels of SOHDG were also found to be 
significantly lower at less than 30 fmol SOHDG/pg DNA, 
P < 0.001). 
GC-MS/SIM was used to confirm the identity of the 
DNA-derived adducts. The partial mass spectra of 8- 
hydroxyadenine, amajor neutrophil-induced DNA dam- 
age product [19], and 8-hydroxyguanine (derived from 
80HDG during hydrolysis) and their abundance at elu- 
tion positions 1 and 2, respectively, are shown in Fig. 2B. 
3.3. Origin of immune complexed DNA 
In order to try and determine the origin of immune 
complexed DNA in SLE sera the DNA present in im- 
mune complexes isolated from SLE sera was purified, 
isolated from the antibody as for cellular DNA, and 
subjected to agarose gel electrophoresis. Approximately 
200 pug of DNA could be isolated from complexes ob- 
tained from 10 ml of plasma, whereas normal cryopre- 
cipitates contained approximately 2-7 pug and RA pa- 
tients 2-8 ,ug. Fig. 3 shows that the immune complexed 
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Fig. 3. A typical gel of DNA isolated from immune complexes of SLE, 
RA and normal control plasma. Lane 1 represents DNA from an RA 
patient; lanes 24, DNA from sera of SLE patients; and lanes 5-7 DNA 
from normal controls. Although the DNA recovered varies in amount, 
there is no significant difference in size. The predominant band of DNA 
corresponds to approximately 20 kb from the compa~son of molecular 
weight markers of lambda DNA cut with the restriction enzymes EcoRI 
and Hind111 which give the Mw profile shown. 
DNA was consistently of the order of 20 kb based upon 
a comparison with M, markers. There was no difference 
in size of DNA from patients with or without renal dis- 
ease, or from patients with RA or the normal controls. 
3.4. Removal of 80HDG during oxidative stress of PBMC 
No significant difference was found between the loss 
of viability for SLE and normal cells incubated in the 
absence of H,O,. In the presence of H20, a significant 
decrease in viability was found both in SLE (P C 0.001) 
and normal (P < 0.001) cells when compared with the 
untreated cells between days 2 and 7 (Fig. 4A and B). 
SLE cells showed a marginally significant reduction in 
135 
viability compared to normal cells under H,O,-induced 
oxidative stress (P < 0.05) between days 2 and 6. 
Parallel extractions of DNA from these cells were 
analysed for the presence of 8OHDG (Fig. 4C,D). Cells 
incubated in the absence of Hz02 had detectable levels 
of 80HDG in the DNA after 4 days. For normal cells 
levels of 80HDG then plateaued at a constant level for 
the remainder of the incubation period. In contrast the 
level of 80HDG in SLE cells continued to rise gradually 
and appeared to be still increasing at day 7. DNA iso- 
lated from cells incubated in the presence of H,O, had 
the highest level of 80HDG at day 1 in both the SLE and 
control groups. In normal cells, this level reached a min- 
imum at day 6. This was not significantly different from 
the level at the equivalent time point in the untreated 
cells. The profile of 80HDG as a component of DNA in 
SLE cells differed from that of the normal cells: whilst 
a similar peak of 80HDG was achieved at day 1, the 
rapid return to baseline was not seen, and instead there 
was a gradual reduction in the level of BOHDG. The 
differences in the two curves at days 2, 4 and 6 were 
significant at P C 0.01. 
80HDG was not detectable in the supernatants from 
normal or SLE PBMC incubated in the absence of H202. 
However, Fig. 4E shows 8OHDG was detectable in the 
supernatants of both SLE and normal PBMC incubated 
with HzOz, reaching a maximum at day 2 in normal cells 
while SLE cells produced a gradual increase over the 
7 day period but reached only 10% of normal maximum 
values at day 2 and 40% of the normal maximum after 
7 days, showing quite clearly a markedly delayed re- 
moval of 80HDG by the SLE cell. 
4. D~cu~ion 
Two patient groups with the inflammatory conditions 
RA or SLE were used to study the role of ROS-induced 
DNA damage in inflammation. 
Patients with SLE have diverse clinical manifestations, 
including arthritis, vasculitis, skin rashes and renal com- 
plications, and the disease is notable for the wide variety 
of antibodies found in the serum; anti-double-stranded 
DNA antibodies being the most specific serological find- 
Table 1 
Comparison of values of 8OHDG found in five cryoprecipitate samples analysed by GCMS and HPLClECD 
Cryoprecipitate 8OHDG 8OHDG DNA pmo180HDG/fig DNA pmo18OHDG/pg DNA 
(pmol, GCMS) (pmol, HPLUECD) @g) (GCMS) (HPLUECD) 
1 78% 6 48& 5 127 +4 0.61 r 0.05 0.37 + 0.04 
2 346 f 13 414* 11 182 Ir 3 1.89 t 0.07 2.27 + 0.06 
3 134+ 5 106+ 6 135+6 0.98 rt 0.03 0.78 f 0.04 
4 217 & 13 222 f 7 118rt7 1.84 t 0‘09 1.88 f 0.06 
5 152+ 8 164f 7 104i5 
Results (means + 1 S.D.) are expressed as pmol 8OHDG/ng DNA of three separate xperiments by both GCMS and HPLCIECD. 
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Fig. 4. The effect of incubating normal and SLE PBMC with 200 ,uM H202 for a maximum of 7 days in terms of (A,B) cell viability, (C,D) 80HDG 
formation in cellular DNA, and (E) corresponding 80HDG formation in supematants of cells. The results are expressed as the mean ir S.D. of three 
separate xperiments. 
ing in SLE. A further abnormality of SLE is the presence 
of circulating immune complexes [24]. 
Rheumatoid arthritis is a chronic, systemic inflamma- 
tory disorder characteristi~lly involving peripheral 
joints [25]. The aetiology is unknown but there is accu- 
mulating evidence that a factor on the D locus of the 
sixth chromosome (DR4/Dw4&Dw 14) occurs in a signif- 
icantly high number of sero-positive cases [26,27]. Evi- 
dence for an autoi~une disturbance in RA rests largely 
upon the presence of serum rheumatoid factors, predom- 
inantly antibodies of the IgM class, reacting with autoio- 
gous immunoglobulins of the IgG class. 
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It has been suggested by several groups that ROS may 
contribute to the development of both RA and SLE and 
both are considered to have ROS-related aetiologies [28]. 
In particular, ROS modification of both IgG [29] and 
DNA [30] can render these macromolecules more suscep- 
tible to forming interactions with circulating autoanti- 
bodies in RA and SLE, respectively, thus promoting 
immune complex formation, which may be important in 
their pathogenesis. The results of 80HDG detection in 
urine and immune complex-derived DNA of SLE and 
RA patients showed that whilst both disease states had 
similar inflammatory components, as determined by 
standard serological markers of inflammatory activity, 
the patterns of DNA damage were very different. RA 
patients responded to increased DNA damage caused 
during inflammation by increasing the output of 80HDG 
in urine. However, in SLE, there was no elevation of 
80HDG excretion with inflammatory activity but an ac- 
cumulation of the altered DNA base in circulating im- 
mune complexes, resulting in a urine output l,~-fold 
lower than in normal controls (as dected by GC-MS/SIM 
in the femtomolar range). 
The results of 80HDG formation as measured by 
HPLC with electrochemical detection rely on the identifi- 
cation of the modified base by its co-elution with a 
known standard. It is possible that other compounds 
present could co-elute with the standard thus either con- 
tributing to the 80HDG peak or giving a false-positive 
result. Since the HPLC technique was unable to give 
de~nitive proof of 80HDG production, both the urine 
and immune complex samples from the SLE and control 
groups were also analysed by GC-MS/SIM. Using this 
technique, identification of modified bases depends not 
only on the co-elution of the compound with its known 
standard but also on a comparison of the mass spectrum 
of the compound with the mass spectrum of the stand- 
ard. Using this technique it was possible to unequivo- 
cally confirm that DNA isolated from the immune com- 
plexes of SLE patients had significantly higher levels of 
80HDG than the corresponding RA control group. It 
was also found that levels of 80HDG in urine from con- 
trols were not significantly different measured by GCMS 
from those measured by HPLC. 
The results from the measurement of SOHDG in rheu- 
matoid patients suggest that, during chronic inflamma- 
tion, increased oxidative stress leads to ROS-mediated 
damage to DNA and that the damage produced (meas- 
ured as 80HDG, though not exclusively) is rapidly and 
efficiently removed from the target cell with a subsequent 
increase in the excretion of the modified base in urine. 
The presence of 80HDG in urine of normal healthy indi- 
viduals also affirms that this altered base is a by-product 
of normal oxidative metabolism and likely to be the 
product of a cellular repair mechanism [20]. The very low 
levels of excreted 80HDG in urine, and the accumulation 
of 80HDG in the circulating immune complexes of SLE 
patients, suggests that there is an abnormal repair of 
damaged DNA in these patients. However, levels of 
80HDG were detected in the femtomolar range in the 
urine of SLE patients, which ruled out a complete defect 
in repair. Alternatively it may be argued that immune 
complexed DNA is very slowly degraded and 80HDG 
may be released into urine via this route. Although it has 
been shown that patients with SLE have defective clear- 
ance m~hanisms for the altered base adduct O-6 meth- 
ylguanine [31], it remains to be determined whether or 
not SOHDG can be repaired by such cells. This may have 
implications in the increased risk of malignancy seen in 
patients with inflammatory disorders since 8OHDG is 
mutagenic, causing faulty base pairing at its location 
132,331. 
Increased sensitivity of SLE cells to ROS-producing 
systems, particularly UV light has been reported previ- 
ously [34,35]; this led us to design experiments to investi- 
gate the efficiency with which SLE cells could repair the 
80HDG adduct induced by incubation of PBMC from 
SLE patients with H,Oz. Our results using H,O1 confirm 
the increased susceptibility of SLE cells to oxidative 
stress on the basis of viability counts. In addition, both 
normal and SLE cells exposed to H,O, showed a rapid 
conversion of dG to 80HDG suggesting that there was 
an equal susceptibility to damage. However, whilst nor- 
mal cells showed a partial removal of the damaged mut- 
agenic base from the DNA paralleled by an increase of 
the base in the supematant, SLE cells showed a consider- 
able decrease in this rate of removal, su~esting an im- 
paired ability to excise 80HDG from the DNA which 
would in turn contribute to the increased number of cells 
dying. These in vitro results are entirely consistent with 
our in vivo data on the excretion of 80HDG in SLE 
urine. Since our results show that the oxidised DNA (as 
shown by the presence of 80HDG as well as several other 
oxidative products of base damage, including 8-hydrox- 
yadenine) that accumulates within the immune com- 
plexes is of the order of 20 kb, consistent with results 
published by other workers [34], we would suggest that 
this DNA has been derived from cell deat~lysis follow- 
ing excessive oxidative injury to the cell, rather than from 
a repair process which may remove several bases up- 
stream or downstream from the altered base. 
In conclusion, we have demonstrated increased ROS- 
mediated damage to DNA in the related chronic infIam- 
matory disorders RA and SLE. However, the way in 
which this damage manifests itself is clearly different in 
each disease. It remains to be clarified whether or not 
cells from SLE patients have an inherent deficiency in the 
repair of 80HDG, and whether this is a phenomenon 
peculiar to lymphocytes or common to all cell types in 
SLE, but the observation of damaged DNA circulating 
in plasma containing high levels of 80HDG in combina- 
tion with our urine and cell studies suggests that SLE 
patients cannot ef%iently remove 80HDG from cellular 
138 
DNA which may result in cell death and release of oxi- 
dised DNA. In addition, we have previously shown that 
denaturation of double-stranded DNA by ROS results 
in an increased binding of anti-DNA antibodies present 
in sera from SLE patients [30] and that ROS modifica- 
tion of human DNA produces a more discriminating 
antigen for the diagnosis of SLE [36]. ROS-damaged 
DNA may, therefore, play a significant role in the gener- 
ation of immune complexes which are of recognised im- 
portance in the pathogenesis of this disease. 
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